These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35309667)

  • 1. RAPD as a clinical alert for early evidence of dysthyroid optic neuropathy.
    Gupta V; Das S; Mohan S; Chauhan U
    J Family Med Prim Care; 2022 Jan; 11(1):370-375. PubMed ID: 35309667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early efficacy of teprotumumab for the treatment of dysthyroid optic neuropathy: A multicenter study.
    Sears CM; Wang Y; Bailey LA; Turbin R; Subramanian PS; Douglas R; Cockerham K; Kossler AL
    Am J Ophthalmol Case Rep; 2021 Sep; 23():101111. PubMed ID: 34113737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical features of dysthyroid optic neuropathy: a European Group on Graves' Orbitopathy (EUGOGO) survey.
    McKeag D; Lane C; Lazarus JH; Baldeschi L; Boboridis K; Dickinson AJ; Hullo AI; Kahaly G; Krassas G; Marcocci C; Marinò M; Mourits MP; Nardi M; Neoh C; Orgiazzi J; Perros P; Pinchera A; Pitz S; Prummel MF; Sartini MS; Wiersinga WM;
    Br J Ophthalmol; 2007 Apr; 91(4):455-8. PubMed ID: 17035276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dysthyroid optic neuropathy: evaluation and management.
    Dolman PJ
    J Endocrinol Invest; 2021 Mar; 44(3):421-429. PubMed ID: 32729049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination Model of Thyrotrophin Receptor Antibody and Volumetric Orbital Apex Crowding Index as an Indicator of Dysthyroid Optic Neuropathy.
    Deng Z; Chen L; Tan J; Wang S; Liu D; Wang J; Jiang C; Yang J; Xu B
    Dis Markers; 2021; 2021():9964232. PubMed ID: 34113406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of isolated-check visual evoked potential technique in dysthyroid optic neuropathy.
    Luo B; Liu R; Wang S; Hu W; Li Y; Tong B; Zhang H; Qi X
    Graefes Arch Clin Exp Ophthalmol; 2023 Jul; 261(7):2031-2040. PubMed ID: 36642765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teprotumumab in advanced reactivated thyroid eye disease.
    Cheng OT; Schlachter DM
    Am J Ophthalmol Case Rep; 2022 Jun; 26():101484. PubMed ID: 35321251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysthyroid optic neuropathy: Demographics, risk factors, investigations, and management outcomes.
    Poonam NS; Alam MS; Oberoi P; Mukherjee B
    Indian J Ophthalmol; 2022 Dec; 70(12):4419-4426. PubMed ID: 36453357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapeutic outcomes and influence factors of maximal orbital decompression in the treatment of severe dysthyroid optic neuropathy].
    Wang Y; Li YY; Yang N; Ma R; Xiao LH
    Zhonghua Yan Ke Za Zhi; 2017 Jun; 53(6):416-423. PubMed ID: 28606262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Dysthyroid optic neuropathy: surgical treatment potential].
    Grusha YO; Ismailova DS; Kochetkov PA; Andreeva NA
    Vestn Oftalmol; 2020; 136(4. Vyp. 2):193-200. PubMed ID: 32880139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visual field and orbital computed tomography correlation in dysthyroid optic neuropathy due to thyroid eye disease.
    Starks VS; Reinshagen KL; Lee NG; Freitag SK
    Orbit; 2020 Apr; 39(2):77-83. PubMed ID: 31057005
    [No Abstract]   [Full Text] [Related]  

  • 12. A pathological indicator for dysthyroid optic neuropathy: tritan color vision deficiency.
    Garip Kuebler A; Halfter K; Reznicek L; Klingenstein A; Priglinger S; Rudolph G; Hintschich C
    Graefes Arch Clin Exp Ophthalmol; 2021 Nov; 259(11):3421-3426. PubMed ID: 34159407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular Hypertension, Glaucoma or Compressive Neuropathy in Patient with Active TED.
    Stoyanova NS; Konareva-Kostianeva MI; Mitkova-Hristova VT
    Folia Med (Plovdiv); 2020 Jun; 62(2):418-423. PubMed ID: 32666771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Therapeutic Effect of Combination of Orbital Decompression Surgery and Methylprednisolone Pulse Therapy on Patients with Bilateral Dysthyroid Optic Neuropathy.
    Xu J; Ye H; Chen G; Chen J; Chen R; Yang H
    J Ophthalmol; 2020; 2020():9323450. PubMed ID: 32148948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical profile and visual outcomes after treatment in patients with dysthyroid optic neuropathy.
    Jeon C; Shin JH; Woo KI; Kim YD
    Korean J Ophthalmol; 2012 Apr; 26(2):73-9. PubMed ID: 22511831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete recovery of visual acuity as the main goal of treatment in patients with dysthyroid optic neuropathy.
    Miśkiewicz P; Rutkowska B; Jabłońska A; Krzeski A; Trautsolt-Jeziorska K; Kęcik D; Milczarek-Banach J; Pirko-Kotela K; Samsel A; Bednarczuk T
    Endokrynol Pol; 2016; 67(2):166-73. PubMed ID: 26884288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyroid-stimulating immunoglobulins indicate the onset of dysthyroid optic neuropathy.
    Ponto KA; Diana T; Binder H; Matheis N; Pitz S; Pfeiffer N; Kahaly GJ
    J Endocrinol Invest; 2015 Jul; 38(7):769-77. PubMed ID: 25736545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subclinical dysthyroid optic neuropathy: tritan deficiency as an early sign of dysthyroid optic neuropathy.
    Garip-Kuebler A; Halfter K; Reznicek L; Klingenstein A; Priglinger S; Hintschich CR
    Br J Ophthalmol; 2021 Jul; 105(7):1019-1023. PubMed ID: 32699051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripapillary and Macular Vessel Density in Dysthyroid Optic Neuropathy: An Optical Coherence Tomography Angiography Study.
    Zhang T; Xiao W; Ye H; Chen R; Mao Y; Yang H
    Invest Ophthalmol Vis Sci; 2019 May; 60(6):1863-1869. PubMed ID: 31042792
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.